Видео ютуба по тегу Trial: Rtog 0617

RTOG 0617: radiation with concurrent chemotherapy and cetuximab in NSCLC
RTOG 0617: radiation with concurrent chemotherapy and cetuximab in NSCLC
Outcomes of secondary analysis for RTOG 0617
Outcomes of secondary analysis for RTOG 0617
Dr. Bradley on the Background of the RTOG 0617 Study in NSCLC
Dr. Bradley on the Background of the RTOG 0617 Study in NSCLC
Impact of radiation dose to immune cells in unresectable or stage III NSCLC in the durvalumab era
Impact of radiation dose to immune cells in unresectable or stage III NSCLC in the durvalumab era
Project 20260215 174132 trial 1
Project 20260215 174132 trial 1
Риск для сердца при раке легких, о котором вам никто не расскажет
Риск для сердца при раке легких, о котором вам никто не расскажет
Assessing SBRT followed by atezolizumab in cervical cancer
Assessing SBRT followed by atezolizumab in cervical cancer
OsteoBites: Simultaneous targeting of CDK4 6 and BETs is independent of RB status in osteosarcoma
OsteoBites: Simultaneous targeting of CDK4 6 and BETs is independent of RB status in osteosarcoma
Phase III trial of catequentinib in pretreated leiomyosarcoma
Phase III trial of catequentinib in pretreated leiomyosarcoma
Первый курс lutetium-177-dota-octreotide. Lu-177. Prrt
Первый курс lutetium-177-dota-octreotide. Lu-177. Prrt
Multicenter Clinical Trial of Real Time Prostate Cancer Diagnosis Using Optical Spectroscopy Guided
Multicenter Clinical Trial of Real Time Prostate Cancer Diagnosis Using Optical Spectroscopy Guided
Cardiac doses of radical radiotherapy impact survival in NSCLC: a real-world analysis
Cardiac doses of radical radiotherapy impact survival in NSCLC: a real-world analysis
Результаты лапароскопической РПЭ у больных РПЖ группы промежуточного риска. Арнаутов А.В.
Результаты лапароскопической РПЭ у больных РПЖ группы промежуточного риска. Арнаутов А.В.
Metabolic-only response assessment for the omission of RNRT for Hodgkin lymphoma: the cHOD17 trial
Metabolic-only response assessment for the omission of RNRT for Hodgkin lymphoma: the cHOD17 trial